Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06744920 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Study acronym: RELIEVE
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Trial sites reduced: 130 → 120 locations · Eligibility criteria expanded, about 8 words · Secondary endpoints: details revised at 14 of 16 entries Show 3 more changesShow less
    • Trial sites reduced: 130 → 120 locations
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 14 of 16 entries
  2. Study sites: 129 to 130 Secondary endpoints: 14 to 16 · Eligibility criteria expanded, about 2 wordsv20 Show 2 more changesShow less
    • Secondary endpoints: 14 to 16
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial sites expanded: 101 → 129 locationsv19
  4. Study sites: 100 to 101v18
  5. Site details revised at 2 of 100 sites Eligibility criteria expanded, about 1 wordv17 Show 1 more changeShow less
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 99 to 100v16
  7. Trial sites expanded: 95 → 99 locationsv15
  8. Study sites: 93 to 95v14
  9. Study sites: 92 to 93v13
  10. Study sites: 88 to 92 Primary completion date: Feb 27, 2028 to Feb 25, 2028v12 Show 1 more changeShow less
    • Primary completion date: Feb 27, 2028 to Feb 25, 2028
  11. Study sites: 86 to 88v11
  12. Study sites: 78 to 86v10
  13. Study sites: 70 to 78v9
  14. Study sites: 64 to 70v8
  15. Study sites: 21 to 64v7
  16. Study sites: 17 to 21 Primary completion date: Feb 25, 2028 to Feb 27, 2028v6 Show 1 more changeShow less
    • Primary completion date: Feb 25, 2028 to Feb 27, 2028
  17. Study sites: 10 to 17v5
  18. Study sites: 1 to 10v4
  19. Re-verified, no change to tracked fieldsv3
  20. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 23, 2024 to Feb 7, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 23, 2024 to Feb 7, 2025
  21. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Myasthenia Gravis
187 trials monitored
See 7 trials at risk
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
Trial Details
NCT Number NCT06744920
Lead Sponsor Novartis Pharmaceuticals
Conditions Generalized Myasthenia Gravis
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov